DCTH Quote, Financials, Valuation and Earnings

CytoSorbents Corp. has a net margin of 4.04% compared to Delcath Systems, Inc.'s net margin of -33.42%. Delcath Systems, Inc.'s return on equity of 1.59% beat CytoSorbents Corp.'s return on equity of -89.32%.

Delcath Systems, Inc. has a consensus price target of $22.33, signalling upside risk potential of 134.35%. On the other hand CytoSorbents Corp. has an analysts' consensus of $5.25 which suggests that it could grow by 709.06%. Given that CytoSorbents Corp. has higher upside potential than Delcath Systems, Inc., analysts believe CytoSorbents Corp. is more attractive than Delcath Systems, Inc..

Delcath Systems, Inc. has a beta of 0.373, which suggesting that the stock is 62.663% less volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.333%.

Delcath Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Delcath Systems, Inc. pays -- of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend.

Delcath Systems, Inc. quarterly revenues are $20.6M, which are larger than CytoSorbents Corp. quarterly revenues of $9.5M. Delcath Systems, Inc.'s net income of $830K is higher than CytoSorbents Corp.'s net income of -$3.2M. Notably, Delcath Systems, Inc.'s price-to-earnings ratio is 1,095.40x while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems, Inc. is 4.54x versus 1.16x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics, Inc. has a net margin of 4.04% compared to Delcath Systems, Inc.'s net margin of 9.12%. Delcath Systems, Inc.'s return on equity of 1.59% beat Quest Diagnostics, Inc.'s return on equity of 14.49%.

Delcath Systems, Inc. has a consensus price target of $22.33, signalling upside risk potential of 134.35%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $217.38 which suggests that it could grow by 7.38%. Given that Delcath Systems, Inc. has higher upside potential than Quest Diagnostics, Inc., analysts believe Delcath Systems, Inc. is more attractive than Quest Diagnostics, Inc..

Delcath Systems, Inc. has a beta of 0.373, which suggesting that the stock is 62.663% less volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.785%.

Delcath Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.58% to investors and pays a quarterly dividend of $0.80 per share. Delcath Systems, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 36.57% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Delcath Systems, Inc. quarterly revenues are $20.6M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Delcath Systems, Inc.'s net income of $830K is lower than Quest Diagnostics, Inc.'s net income of $256M. Notably, Delcath Systems, Inc.'s price-to-earnings ratio is 1,095.40x while Quest Diagnostics, Inc.'s PE ratio is 23.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems, Inc. is 4.54x versus 2.07x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Danaher Corp. has a net margin of 4.04% compared to Delcath Systems, Inc.'s net margin of 17.3%. Delcath Systems, Inc.'s return on equity of 1.59% beat Danaher Corp.'s return on equity of 7.02%.

Delcath Systems, Inc. has a consensus price target of $22.33, signalling upside risk potential of 134.35%. On the other hand Danaher Corp. has an analysts' consensus of $264.91 which suggests that it could grow by 25.4%. Given that Delcath Systems, Inc. has higher upside potential than Danaher Corp., analysts believe Delcath Systems, Inc. is more attractive than Danaher Corp..

Delcath Systems, Inc. has a beta of 0.373, which suggesting that the stock is 62.663% less volatile than S&P 500. In comparison Danaher Corp. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.434%.

Delcath Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher Corp. offers a yield of 0.61% to investors and pays a quarterly dividend of $0.32 per share. Delcath Systems, Inc. pays -- of its earnings as a dividend. Danaher Corp. pays out 25.35% of its earnings as a dividend. Danaher Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Delcath Systems, Inc. quarterly revenues are $20.6M, which are smaller than Danaher Corp. quarterly revenues of $6.8B. Delcath Systems, Inc.'s net income of $830K is lower than Danaher Corp.'s net income of $1.2B. Notably, Delcath Systems, Inc.'s price-to-earnings ratio is 1,095.40x while Danaher Corp.'s PE ratio is 41.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems, Inc. is 4.54x versus 6.16x for Danaher Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Odyssey Health, Inc. has a net margin of 4.04% compared to Delcath Systems, Inc.'s net margin of --. Delcath Systems, Inc.'s return on equity of 1.59% beat Odyssey Health, Inc.'s return on equity of --.

Delcath Systems, Inc. has a consensus price target of $22.33, signalling upside risk potential of 134.35%. On the other hand Odyssey Health, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Delcath Systems, Inc. has higher upside potential than Odyssey Health, Inc., analysts believe Delcath Systems, Inc. is more attractive than Odyssey Health, Inc..

Delcath Systems, Inc. has a beta of 0.373, which suggesting that the stock is 62.663% less volatile than S&P 500. In comparison Odyssey Health, Inc. has a beta of -1.030, suggesting its less volatile than the S&P 500 by 202.982%.

Delcath Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Odyssey Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Delcath Systems, Inc. pays -- of its earnings as a dividend. Odyssey Health, Inc. pays out -- of its earnings as a dividend.

Delcath Systems, Inc. quarterly revenues are $20.6M, which are larger than Odyssey Health, Inc. quarterly revenues of --. Delcath Systems, Inc.'s net income of $830K is higher than Odyssey Health, Inc.'s net income of -$483.4K. Notably, Delcath Systems, Inc.'s price-to-earnings ratio is 1,095.40x while Odyssey Health, Inc.'s PE ratio is 0.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems, Inc. is 4.54x versus -- for Odyssey Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.